Status:
UNKNOWN
Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma
Lead Sponsor:
Lei Li
Conditions:
Recurrent Cervical Carcinoma
Radiotherapy
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
Patients with recurrent or metastatic uterine cervical squamous carcinoma have very poor prognosis. For eligible patients, radiotherapy remains the choice, which has the most effective impact on the s...
Eligibility Criteria
Inclusion
- Female aged more than 18 years
- Eastern Cooperative Oncology Group score 0-1
- Pathological confirmed of uterine cervical squamous carcinoma
- An interval of 3 months or more since the fulfilling of last treatment
- At least one measurable lesion defined by Response Evaluation Criteria in Solid Tumors (RECIST) guideline 1.1
- Anticipative survival period of 3 months or more
- Lab testing within reference ranges
- With appropriate contraception
- Provided consents of participating the trial
Exclusion
- With a history of exposure to other antiangiogenic agents
- With other malignancies within past 3 years
- With vital complications
- With uncontrolled hypertension despite of medical treatment
- With brain metastasis
- With addiction to psychiatric medications or with mental disorders
Key Trial Info
Start Date :
December 19 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT04664244
Start Date
December 19 2020
End Date
December 31 2023
Last Update
December 22 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lei Li
Beijing, Beijing Municipality, China, 100730